User profiles for Pierre Wolkenstein

Pierre Wolkenstein

APHP UPEC
Verified email at u-pec.fr
Cited by 23651

[HTML][HTML] SCORTEN: a severity-of-illness score for toxic epidermal necrolysis

…, JC Roujeau, J Revuz, P Wolkenstein… - Journal of Investigative …, 2000 - Elsevier
The mortality of toxic epidermal necrolysis is about 30%. Our purpose was to develop and
validate a specific severity-of-illness score for cases of toxic epidermal necrolysis admitted to a …

[HTML][HTML] Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation

E Legius, L Messiaen, P Wolkenstein, P Pancza… - Genetics in …, 2021 - nature.com
Purpose By incorporating major developments in genetics, ophthalmology, dermatology,
and neuroimaging, to revise the diagnostic criteria for neurofibromatosis type 1 (NF1) and to …

Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies

JE Revuz, F Canoui-Poitrine, P Wolkenstein… - Journal of the American …, 2008 - Elsevier
BACKGROUND: Conflicting opinions have been reported regarding the epidemiology of
hidradenitis suppurativa. OBJECTIVE: We sought to evaluate the prevalence of hidradenitis …

Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis

P Wolkenstein, J Latarjet, JC Roujeau, C Duguet… - The Lancet, 1998 - thelancet.com
… Christian Brun-Buisson participated on the safety board and analysed the data with Pierre
Wolkenstein. Pierre Wolkenstein, Jean-Claude Roujeau, Christian Brun-Buisson, and Jean …

Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells

…, A Deniaud, H Moslehi, P Wolkenstein… - Journal of allergy and …, 2004 - Elsevier
BACKGROUND: Toxic epidermal necrolysis (TEN) is a very rare but extremely severe drug
reaction characterized by widespread apoptosis of epidermis with extensive blisters. We …

Quality of life impairment in hidradenitis suppurativa: a study of 61 cases

P Wolkenstein, A Loundou, K Barrau, P Auquier… - Journal of the American …, 2007 - Elsevier
OBJECTIVE: We sought to determine quality of life impairment in hidradenitis suppurativa.
METHODS: Questionnaires were administered to 61 patients. RESULTS: Quality of life impact …

Severe cutaneous adverse reactions to drugs

TA Duong, L Valeyrie-Allanore, P Wolkenstein… - The Lancet, 2017 - thelancet.com
During the past decade, major advances have been made in the accurate diagnosis of severe
cutaneous adverse reactions (SCARs) to drugs, management of their manifestations, and …

Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity

F Canoui-Poitrine, JE Revuz, P Wolkenstein… - Journal of the American …, 2009 - Elsevier
BACKGROUND: Factors associated with the severity of hidradenitis suppurativa (HS) are
not known. OBJECTIVE: We sought to identify factors associated with the severity of HS. …

Patch testing in severe cutaneous adverse drug reactions, including Stevens‐Johnson syndrome and toxic epidermal necrolysis

P Wolkenstein, O Chosidow, ML Fléchet… - Contact …, 1996 - Wiley Online Library
Patch testing may help to assess the culpability of a drug in an adverse reaction. Our aim
was to study patch testing in severe cutaneous ad verse drug reactions [ADRs] (Stevens‐…

Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1) A retrospective study of 104 patients

…, M Zerah, M Sanson, S Bastuji‐Garin, P Wolkenstein - Brain, 2002 - academic.oup.com
In addition to multiple peripheral neurofibromas, Neurofibromatosis 1 (NF1) predisposes to
CNS tumours. Most of them are pilocytic astrocytomas, arise in children and are located in …